Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses

European Journal of Immunology

Volumn 39, Issue 1, 2009, Pages 159-177

  Midha, Shuchi ^a   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Anthrax; DNA vaccination; Protease cleaved fragment; Protective antigen

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEUTRALIZING ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; UBIQUITIN; ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; CYTOKINE; LAMP1 PROTEIN, MOUSE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL IMMUNITY; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTECTION; ANIMAL; BAGG ALBINO MOUSE; BIOLISTIC TRANSFORMATION; BLOOD; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BIOLISTICS; CYTOKINES; FEMALE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; TISSUE PLASMINOGEN ACTIVATOR; UBIQUITIN; VACCINATION; VACCINES, DNA;

EID: 60549095969     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838058     Document Type: Article

References (86)

1. Mock, M. and Fouet, A., Anthrax. Annu. Rev. Microbiol. 2001. 55: 647-671.
2. Wang, J. Y. and Roehrl, M. H., Anthrax vaccine design: Strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol. 2005. 4: 4-11.
3. Joellenbeck, L., Zwanziger, L., Durch, J. and Strom, B., (Eds). The Anthrax Vaccine. Is It Safe? Does It Work? National Academy Press, Washington, DC 2002.
4. Milne, J. C., Furlong, D., Hanna, P. C., Wall, J. S. and Collier, R. J., Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 1994. 269: 20607-20612.
5. Miller, C. J., Elliott, J. L. and Collier, R. J., Anthrax protective antigen: Prepore-to-pore conversion. Biochemistry 1999. 38: 10432-10441.
6. Collier, R. J., Mechanism of membrane translocation by anthrax toxin: Insertion and pore formation by protective antigen. J. Appl. Microbiol. 1999. 87: 283.
7. Mogridge, J., Cunningham, K., Lacy, D. B., Mourez, M. and Collier, R. J., The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci. USA 2002. 99: 7045-7048.
8. Turk, B. E., Manipulation of host signalling pathways by anthrax toxins. Biochem. J. 2007. 402: 405-417.
9. Duesbery, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., Copeland, T. D., Ahn, N. G. et al., Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998. 280: 734-737.
10. Vitale, G., Bernardi, L., Napolitani, G., Mock, M. and Montecucco, C., Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000. 352: 739-745.
11. Park, J. M., Greten, F. R., Li, Z.W. and Karin, M., Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002. 297: 2048-2051.
12. Paccani, S. R., Tonello, F., Ghittoni, R., Natale, M., Muraro, L., D'Elios, M. M., Tanget, W.-J. et al., Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 2005. 201: 325-331.
13. Leppla, S. H., Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 1982. 79: 3162-3166.
14. Leppla, S. H., Bacillus anthracis calmodulin-dependent adenylate cyclase: Chemical and enzymatic properties and interactions with eucaryotic cells. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1984. 17: 189-198.
15. Wright, G. G. and Mandell, G. L., Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. Med. 1986. 164: 1700-1709.
16. O'Brien, J., Friedlander, A., Dreier, T., Ezzell, J. and Leppla, S. H., Effects of anthrax toxin components on human neutrophils. Infect. Immun. 1985. 47: 306-310.
17. Cleret, A., Quesnel-Hellmann, A., Mathieu, J., Vidal, D., and Tournier, J. N., Resident CD11c+ lung cells are impaired by anthrax toxins after spore infection. J. Infect. Dis. 2006. 194: 86-94.
18. Mulligan, M. J., Russell, N. D., Celum, C., Kahn, J., Noonan, E., Montefiori, D. C., Ferrari, G. et al., Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses 2006. 22: 678-683.
19. Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smithet, C. et al., Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006. 24: 417-425.
20. Calarota, S., Bratt, G., Nordlund, S., Hinkula, J., Leandersson, A. C., Sandström, E. and Wahren, B., Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998. 351: 1320-1325.
21. MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J., Bagarazzi, M. L., Chattergoon, M. A. et al., First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis. 1998. 178: 92-100.
22. Wang, R., Doolan, D. L., Le, T. P., Hedstrom, R. C., Coonan, K. M., Charoenvit, Y., Jones, T. R. et al., Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998. 282: 476-480.
23. Hermanson, G., Whitlow, V., Parker, S., Tonsky, K., Rusalov, D., Ferrari, M., Lalor, P. et al., A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. USA 2004. 101: 13601-13606.
24. Park, Y. S., Lee, J. H., Hung, C. F., Wu, T. C. and Kim, T. W., Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 2008. 76: 1952-1959.
25. Price, B. M., Liner, A. L., Park, S., Leppla, S. H., Mateczun, A. and Galloway, D. R., Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 2001. 69: 4509-4515.
26. Sloat, B. R. and Cui, Z., Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm. Res. 2006. 23: 262-269.
27. Ribeiro, S., Rijpkema, S. G., Durrani, Z. and Florence, A. T., PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int. J. Pharm. 2007. 331: 228-232.
28. Galloway, D., Liner, A., Legutki, J., Mateczun, A., Barnewall, R. and Estep, J., Genetic immunization against anthrax. Vaccine 2004. 22: 1604-1608.
29. Hahn, U. K., Alex, M., Czerny, C. P., Böhm, R. and Beyer, W., Protection of mice against challenge with Bacillus anthracis ST1 spores after DNA vaccination. Int. J. Med. Microbiol. 2004. 294: 35-44.
30. Perkins, S. D., Flick-Smith, H. C., Garmory, H. S., Essex-Lopresti, A. E., Stevenson, F. K. and Phillpotts, R. J., Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax. Genet. Vaccines Ther. 2005. 3: 3.
31. Nuchtern, J. G., Biddison, W. E. and Klausner, R. D., Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990. 343: 74-76.
32. Honing, S. and Hunziker, W., Cytoplasmic determinants involved in direct lysosomal sorting, endocytosis, and basolateral targeting of rat lgp120 (lamp-I) in MDCK cells. J. Cell. Biol. 1995. 128: 321-332.
33. Drake, J. R., Lewis, T. A., Condon, K. B., Mitchell, R. N. and Webster, P., Involvement of MIIC-like late endosomes in B cell receptor-mediated antigen processing in murine B cells. J. Immunol. 1999. 162: 1150-1155.
34. Li, Z., Howard, A., Kelley, C., Delogu, G., Collins, F. and Morris, S., Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect. Immun. 1999. 67: 4780-4786.
35. Castiglioni, P., Gerloni, M., Cortez-Gonzalez, X. and Zanetti, M., CD8+ T cell priming by B lymphocytes is CD4+ help dependent. Eur. J. Immunol. 2005. 35: 1360-1370.
36. Holowaty, M. N., Sheng, Y., Nguyen, T., Arrowsmith, C. and Frappier, L., Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J. Biol. Chem. 2003. 278: 47753-47761.
37. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. et al., Inhibitors of proteasome block the degradation of proteins and the generation of peptides presented on MHC-I antigen presentation pathway. Cell 1994. 78: 761-771.
38. Staats, H. F., Alam, S. M., Scearce, R. M., Kirwan, S. M., Zhang, J. X., Gwinn, W. M. and Haynes, B. F., In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 2007. 75: 5443-5452.
39. Finkelman, F. D., Holmes, J., Katona, I. M., Urban, J. F., Jr. , Beckmann, M. P., Park, L. S. and Schooley, K. A., Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990. 8: 303-333.
40. Spiegelberg, H. L., Biological role of different antibody classes. Int. Arch. Allergy Appl. Immunol. 1989. 90(Suppl 1): 22-27.
41. Welkos, S., Little, S., Friedlander, A., Fritz, D. and Fellows, P., The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001. 147: 1677-1685.
42. Welkos, S., Friedlander, A., Weeks, S., Little, S. and Mendelson, I., In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol. 2002. 51: 821-831.
43. Cote, C. K., Rossi, C. A., Kang, A. S., Morrow, P. R., Lee, J. S. and Welkos, S. L., The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb. Pathog. 2005. 38: 209-225.
44. Little, S. F., Leppla, S. H. and Cora, E., Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 1988. 56: 1807-1813.
45. Reuveny, S., White, M. D., Adar, Y. Y., Kafri, Y., Altboum, Z., Gozes, Y., Kobiler, D. et al., Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 2001. 69: 2888-2893.
46. Weiss, S., Kobiler, D., Levy, H., Marcus, H., Pass, A., Rothschild, N. and Altboum, Z., Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 2006. 74: 394-398.
47. Peachman, K. K., Rao, M., Alving, C. R., Burge, R., Leppla, S. H., Rao, V. B. and Matyas, G. R., Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect. Immun. 2006. 74: 794-797.
48. Gold, H., Treatment of anthrax. Fed. Proc. 1967. 26: 1563-1568.
49. Turnbull, P. C. B., Leppla, S. H., Broster, M. G., Quinn, C. P. and Melling, J., Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. 1988. 177: 293-303.
50. Little, S. F., Ivins, B. E., Fellows, P. F. and Friedlander, A. M., Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 1997. 65: 5171-5175.
51. Albrecht, M. T., Li, H., Williamson, E. D., LeButt, C. S., Flick-Smith, H. C., Quinn, C. P., Westra, H. et al., Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 2007. 75: 5425-5433.
52. Pittman, P. R., Kim-Ahn, G., Pifat, D. Y., Coonan, K., Gibbs, P., Little, S., Pace-Templeton, J. G. et al., Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002. 20: 1412-1420.
53. Marcus, H., Danieli, R., Epstein, E., Velan, B., Shafferman, A. and Reuveny, S., Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect. Immun. 2004. 72: 3471-3477.
54. Fellows, P. F., Linscott, M. K., Ivins, B. E., Pitt, M. L. M., Rossi, C. A., Gibbs, P. and Friedlander, A.M., Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographic origin. Vaccine 2001. 19: 3241-3247.
55. Little, S. F., Ivins, B. E., Fellows, P. F., Pitt, M. L., Norris, S. L. and Andrews, G. P., Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004. 22: 422-430.
56. Little, S. F., Ivins, B. E., Webster, W. M., Fellows, P. F., Pitt, M. L., Norris, S. L. and Andrews, G. P., Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 2006. 24: 2530-2536.
57. McBride, B.W., Mogg, A., Telfer, J. L., Lever, M. S., Miller, J., Turnbull, P. C. and Baillie, L., Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998. 16: 810-817.
58. Friedlander, A. M., Pittman, P. R. and Parker, G. W., Anthrax vaccine: Evidence for safety and efficacy against inhalational anthrax. J. Am. Med. Assoc. 1999. 282: 2104-2146.
59. Kaech, S. M., Wherry, E. J. and Ahmed, R., Effector and memory T-cell differentiation: Implications for vaccine development. Nat. Rev. Immunol. 2002. 2: 251-262.
60. Glomski, I. J., Corre, J. P., Mock, M. and Goossens, P. L., Cutting Edge: IFN-gamma-producing CD4+ T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J. Immunol. 2007. 178: 2646-2650.
61. Shiau, Y. T., Huang, Y. H., Wu, J. C., Tao, M. H., Syu, W., Jr., Chang, F. Y. and Lee, S. D., Analysis of humoral immunity of Hepatitis D virus DNA vaccine generated in mice by using different dosage, gene gun immunization, and in vivo electroporation. J. Chin. Med. Assoc. 2006. 69: 7-13.
62. Yasutomi, Y., Robinson, H. L., Lu, S., Mustafa, F., Lekutis, C., Arthos, J., Mullins, J. I. et al., Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of Rhesus monkeys. J. Virol. 1996. 70: 678-681.
63. Mellman, I., Endocytosis and antigen processing. Semin. Immunol. 1990. 2: 229-237.
64. Fernandes, D. M., Vidard, L. and Rock, K. L., Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments. Eur. J. Immunol. 2000. 30: 2333-2343.
65. Baillie, L., Townend, T., Walker, N., Eriksson, U. and Williamson, D., Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol. Med. Microbiol. 2004. 42: 267-270.
66. Abrami, L., Liu, S., Cosson, P., Leppla, S. H. and van der, F. G. G., Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 2003. 160: 321-328.
67. Peterson, J.W., Comer, J. E., Baze, W. B., Noffsinger, D.M., Wenglikowski, A., Walberg, K. G. and Hardcastle, J., Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun. 2007. 75: 3414-3424.
68. Brulet, J. M., Maudoux, F., Thomas, S., Thielemans, K., Burny, A., Leo, O., Bex, F. and Hallez, S., DNA vaccine encoding endosometargeted human papillomavirus type 16 E7 protein generates CD41 T cell-dependent protection. Eur. J. Immunol. 2007. 37: 376-384.
69. Turnbull, P. C., Broster, M. G., Carman, J. A., Manchee, R. J. and Melling, J., Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 1986. 52: 356-363.
70. Farr, R. S. and Dixon, F. J., Jr., The effect of antigen concentration on the initiation of detectable antibody synthesis in rabbits. J. Immunol. 1960. 85: 250-257.
71. Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kundig, T. and Hengartner, H., Antigen localization regulates immune responses in a dose and time-dependent fashion: A geographical view of immune reactivity. Immunol. Rev. 1997. 156: 199-209.
72. Pitt, M. L. M., Little, S. F., Ivins, B. E., Fellows, P. F., Barth, J., Hewetson, J., Gibbs, P. et al., In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001. 19: 4768-4773.
73. Vogel, F. R., Immunologic adjuvants for modern vaccine formulations. Ann. NY Acad. Sci. 1995. 754: 153-160.
74. Fang, H., Cordoba-Rodriguez, R., Lankford, C. S. and Frucht, D. M., Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells. J. Immunol. 2005. 174: 4966-4971.
75. Comer, J. E., Chopra, A. K., Peterson, J. W. and König, R., Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect. Immun. 2005. 73: 8275-8281.
76. Gupta, P., Waheed, S. M. and Bhatnagar, R., Expression and purification of the recombinant protective antigen of Bacillus anthracis. Protein Expr. Purif. 1999. 16: 369-376.
77. Franken, K. L., Hiemstra, H. S., van Meijgaarden, K. E., Subronto, Y., den Hartigh, J., Ottenhoff, T. H. M. and Drijfhout, J. W., Purification of His-tagged proteins by immobilized chelate affinity chromatography: The benefits from the use of the organic solvents. Protein Expr. Purif. 2000. 18: 95-99.
78. Balch, W. E., Dunphy, W. G., Braell, W. A. and Rothman, J. E., Reconstitution of the transport of protein between successive compartments of the Golgi measured by the coupled incorporation of N-acetylglucosamine. Cell 1984. 39: 405-416.
79. Brown, A. J., Mander, E. L., Gelissen, I. C., Kritharides, L., Dean, R. T. and Jessup, W., Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. Accumulation of oxidized esters in lysosomes. J. Lipid Res. 2000. 41: 226-237.
80. Koldovský, O. and Palmieri, M., Cortisone-evoked decrease of acid-galactosidase, glucuronidase, N-acetyl-glucosaminidase and arylsulphatase in the ileum of suckling rats. Biochem. J. 1971. 125: 697-701.
81. Boyaka, P. N., Tafaro, A., Fischer, R., Leppla, S. H., Fujihashi, K. and McGhee, J. R., Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 2003. 170: 5636-5643.
82. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M. and Strober W., Current Protocols in Immunology, Wiley, New York, NY 1994.
83. Esquifino, A. L., Szary, A., Brown-Borg, H. M. and Bartke, A., Age related effects of ectopic pituitary transplants on activation of Ames dwarf mouse lymphocytes in vitro. Proc. Soc. Exp. Biol. Med. 1996. 211: 87-93.
84. Martinez, C., Delgado, M., Gomariz, R. P. and Ganea, D., Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 1996. 156: 4128-4136.
85. He, Y., Vemulapalli, R., Zeytun, A. and Gerhardt, G., Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infect. Immun. 2001. 69: 5502-5508.
86. D' Souza, V. A., Pannuti, C. S., Sumita, L. M., Andrade, H., Franco, de., Jr., Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J. Med. Virol. 1997. 52: 275-279.